SCHEMBL30601616

SCHEMBL30601616

COc1ccccc1C(=O)Nc1nc2ccccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 1.00
RAB9A P51151 13/20 1.00
PKM P14618 6/20 1.00
HSP90AA1 P07900 2/20 1.00
PAX8 Q06710 1/20 1.00
KLF5 Q13887 2/20 0.74
POLB P06746 1/20 0.74
TDP1 Q9NUW8 1/20 0.74
SMN1; SMN2 Q16637 5/20 0.68
TP53 P04637 3/20 0.68
USP2 O75604 1/20 0.68
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
LMNA P02545 3/20 0.66
GAA P10253 1/20 0.66
RXFP1 Q9HBX9 1/20 0.64
MAPT P10636 1/20 0.64
TSHR P16473 2/20 0.63
FOXO1 Q12778 1/20 0.62
OPRK1 P41145 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15550757 1.00 NPC1 (1.00) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL13568267 0.90 RAB9A (0.82) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL11706323 0.86 NPC1 (0.83) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL11706220 0.85 NPC1 (0.74) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL16221498 0.84 RAB9A (1.00) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL15552047 0.83 RAB9A (0.70) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL2243443 0.82 NPC1 (0.72) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL11705400 0.81 NPC1 (0.74) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL30933683 0.81 RAB9A (0.67) NPC1RAB9APKMHSP90AA1PAX8
SCHEMBL18359050 0.80 RAB9A (0.67) NPC1RAB9APKMHSP90AA1PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES Didenko, Kirill (US) 2025-07-03 US disclosed
CN-120091810-A Methods and highly bioavailable permeable compounds for treating viral diseases 基里尔·迪丹克 2025-06-03 CN disclosed
WO-2023187599-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES DIDENKO KIRILL (MX) 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES ACE2, FURIN, SARS1 NPC1 23/4885RAB9A 1443/4885PKM 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.